# US 2012/0252828 A1 · Pyridoquinazolinone m1 receptor positive allosteric modulators

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252828 A1
- Document ID: US20120252828A1
- Status: Published application
- Kind: A1
- Application number: 13/515,512
- Filed: 2010-12-09
- Published: 2012-10-04
- Earliest claimed: 2009-12-14
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Scott D. Kuduk; Ronald K. Chang; Thomas J. Greshock
- Web page: https://patentgrep.com/patent/US20120252828A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

## Claims

### Claim 1

A compound of formula (I):
wherein R1 is selected from the group consisting of
(1) —C6-10 aryl, or
(2) heteroaryl, wherein the heteroaryl is an aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
wherein each aryl or heteroaryl is optionally substituted with one or more R2 group;
R2 is selected from the group consisting of
(1) halogen,
(2) —C1-6 alkyl,
(3) —C2-8 alkenyl,
(4) —O—C1-6 alkyl,
(5) —S—C1-6 alkyl,
(6) —C(═O)—(O)n—R4,
(7) —C6-10 aryl,
(8) heteroaryl, which is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
(9) —NR5R6,
wherein said alkyl, alkenyl, aryl or heteroaryl R2 group is optionally substituted with one or more
(a) halogen,
(b) —C1-6 alkyl,
(c) —C3-8 cycloalkyl,
(d) —NR7R8,
(e) —O—C1-6 alkyl,
(f) C6-10 aryl,
(g) CN, or
(h) hydroxyl
wherein said alkyl, cycloalkyl or aryl is optionally substituted with one or more
(i) halogen,
(ii) hydroxyl,
(iii) —NR9R10;
X and Y are selected from the group consisting of
(1) CH2, or
(2) O,
wherein one of X or Y is O, then the other is CH2;
Q1, Q2, Q3 and Q4 are each selected from the group consisting of
(1) N, or
(2) CR3,
provided that one of Q1, Q2, Q3 or Q4 is N and the others are each CR3;
R3 is selected from the group consisting of
(1) hydrogen,
(2) halogen,
(3) —C1-6 alkyl, or
(4) —O—C1-6 alkyl;
R4 is selected from the group consisting of
(1) hydrogen,
(2) —C1-6 alkyl,
(3) —C3-8 cycloalkyl,
(4) —C2-6 alkenyl,
(5) —C0-2 alkyl-C6-10 aryl,
(6) —C0-2 alkyl-heteroaryl group, wherein the heteroaryl is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S, wherein said alkyl, alkenyl, aryl or heteroaryl R7 group is optionally substituted with one or more
(a) halogen,
(b) hydroxy,
(c) —O—C1-6 alkyl,
(d) —C1-6 alkyl, optionally substituted with halogen;
R5 and R6, or R7 and R8, or R9 and R10 are each independently selected from the group consisting of
(1) hydrogen,
(2) —C1-6 alkyl,
(3) —C3-8 cycloalkyl, or
(4) —C6-10 aryl,
wherein said alkyl, cycloalkyl or aryl is optionally substituted with one or more
(a) halogen,
(b) —C1-6 alkyl,
(c) —C3-8 cycloalkyl,
(d) —O—C1-6 alkyl,
(e) —C6-10 aryl,
(f) heteroaryl, which is an aromatic cyclic or polycyclic cyclic, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O), SO2 or S, at least one of which is O, N, N→O, SO2 or S,
or R5 and R6, or R7 and R8, or R9 and R10 are linked together with the nitrogen to which they are both attached to form a 4-8 membered carbocyclic ring, wherein one or two of the ring carbon atoms is replaced by a nitrogen, oxygen or sulfur, and the carbocyclic is optionally substituted with one or more
(a) halogen,
(b) —C1-6 alkyl,
(c) —O—C1-6 alkyl, or
(d) —C6-10 aryl,
n is 0 or 1;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is phenyl, wherein the phenyl is substituted by one R2 group, which is para to the methylene group that binds the phenyl to the core, and each R2 is selected from the group consisting of
(1) halogen,
(2) —C1-6 alkyl,
(3) —C2-8 alkenyl,
(4) —O—C1-6 alkyl,
(5) —S—C1-6 alkyl,
(7) —C6-10 aryl (typically, phenyl), or
(8) heteroaryl, which is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
(9) —NR5R6,
wherein said alkyl, alkenyl, aryl or heteroaryl R2 group is optionally substituted as described above.

### Claim 3 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is heteroaryl, wherein the heteroaryl is an
aromatic cyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,

### Claim 4 (depends on 1)

A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Q2 is N, and each of Q1, Q3 and Q4 is CR3.

### Claim 5 (depends on 1)

A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Q4 is N, and each of Q1, Q2 and Q3 is CR3.

### Claim 6 (depends on 1)

A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X and Y are both CH2.

### Claim 7 (depends on 1)

A compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is CH2 and Y is O.

### Claim 8 (depends on 1)

A compound of claim 1, wherein the compound of formula (I) is a compound of formula (II)
or a pharmaceutically acceptable salt thereof, wherein Y, R2, Q1, Q2, Q3 and Q4 are as defined in claim 1.

### Claim 9 (depends on 8)

A compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of
(1) halogen,
(2) —C1-6 alkyl,
(3) —C2-8 alkenyl,
(4) —O—C1-6 alkyl,
(5) —S—C1-6 alkyl, or
(6) heteroaryl, which is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S,
wherein said alkyl, alkenyl, aryl or heteroaryl R2 group is optionally substituted as described above.

### Claim 10 (depends on 1)

A compound of claim 1, wherein the compound of formula (I) is a compound of formula (III):
or a pharmaceutically acceptable salt thereof, wherein Y, R2, Q1, Q2, Q3 and Q4 are as defined in claim 1.

### Claim 11 (depends on 10)

A compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein R2 is selected from the group consisting of
(1) halogen,
(2) —C1-6 alkyl,
(3) —C2-8 alkenyl,
(4) —O—C1-6 alkyl,
(5) —S—C1-6 alkyl, or
(6) heteroaryl, which is an aromatic cyclic or polycyclic group, having from five to twelve ring atoms, said ring atoms selected from C, O, N, N→O, C(═O) or S, at least one of which is O, N, N→O or S.

### Claim 12 (depends on 1)

A compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound of formula (I) is a compound of formula (IV)
or a pharmaceutically acceptable salt thereof, wherein Y and R1 are as described

### Claim 13 (depends on 1)

A compound of claim 1, which is selected from the group consisting of
6-[(6-Chloropyridin-3-yl)methyl]-3-[(1S,2S)-2-hydroxycyclohexyl]pyrido[3,4-h]quinazolin-4(3H)-one;
6-[(6-Chloropyridin-3-yl)methyl]-3-[(3R,4S)-3-hydroxytetrahydro-2H-pyran-4-yl]pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methoxypyridin-3-yl)methyl]pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-{[6-(methylthio)pyridine-3-yl]methyl}pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-{[6-(1H-pyrazol-1-yl)pyridine-3-yl]methyl}pyrido[2,3-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-{[6-(1-methyl-1H-pyrazol-4-yl)pyridine-3-yl]methyl}pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-pyrazin-2-ylpyridin-3-yl)methyl]pyrido[3,4-h]quinazolin-4(3H)-one;
4-({3-[(1S,2S)-2-Hydroxycyclohexyl]-4-oxo-3,4-dihydropyrido[3,4-h]quinazolin-6-yl}methyl)benzaldehyde;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[4-(1-hydroxyethyl)benzyl]pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[4-(1-hydroxypropyl)benzyl]pyrido[3,4-h]quinazolin-4(3H)-one;
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-(4-morpholin-4-ylbenzyl)pyrido[3,4-h]quinazolin-4(3H)-one; and
3-[(3S,4S)-4-Hydroxytetrahydro-2H-pyran-3-yl]-6-[(2-methylpyridin-4-yl)methyl]pyrido[2,3-h]quinazolin-4(3H)-one;
or a pharmaceutically acceptable salt thereof.

### Claim 14 (depends on 1)

A compound of claim 1, which is a compound of formula (IA)
wherein R1 is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A compound of claim 1, which is a compound of Formula (IB),
wherein R11, Q5 and Q6 are grouped as follows:
Q5
Q6
R11
N
N
CH
CH
CH
CH
CH
H
CH
H
CH
Cl
CH
Br
CH
Br
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
CH
OMe
CH
OMe
CH
Me
CH
Me
CH
F
CH
F
CH
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A compound of claim 1, which is a compound of Formula (IC)
wherein Q5 and R11 are grouped as follows:
Q5
R11
OMe
OMe
Me
Me
F
F
or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A compound of claim 1, which is a compound of Formula (ID), wherein R11, Q5 and Q6 are grouped as follows:
Q5
Q6
R11
N
Cl
N
Me
N
N
N
N
N
Cl
N
Me
CH
F
CH
Cl
CH
OMe
N
SMe
CH
Br
N
N
N
Et
N
N
OMe
N
or a pharmaceutically acceptable salt thereof.

### Claim 18

wherein R is selected from the group consisting of
or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

Use of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, for the manufacture of a medicament for the treatment of a disease or disorder mediated by the muscarinic M1 receptor, wherein said disease or disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders.

### Claim 21 (depends on 1)

A method of treating a disease or disorder mediated by the muscarinic M1 receptor, wherein said disease or disorder is selected from the group consisting of Alzheimer's disease, schizophrenia, pain or sleep disorders in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
